Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
Top Cited Papers
- 23 December 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 19 (5), 1508-1516
- https://doi.org/10.1245/s10434-011-2108-2
Abstract
The use of neoadjuvant systemic therapy (NST) for the treatment of primary breast cancer has constantly increased, especially in trials of new therapeutic regimens. In the 1980 s, NST was shown to substantially improve breast-conserving surgery rates and was first typically used for patients with inoperable locally advanced or inflammatory breast cancer. Investigators have since also used NST as an in vivo test for chemosensitivity by assessing pathologic complete response. Today, by using pathologic response and other biomarkers as intermediate end points, results from trials of new regimens and therapies that use NST are aimed to precede and anticipate the results from larger adjuvant trials. In 2003, a panel of representatives from various breast cancer clinical research groups was first convened in Biedenkopf to formulate recommendations on the use of NST. The obtained consensus was updated in two subsequent meetings in 2004 and 2006. The most recent conference on recommendations on the use of NST took place in 2010 and forms the basis of this report.Keywords
This publication has 64 references indexed in Scilit:
- Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline featuresBreast Cancer Research and Treatment, 2010
- International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatmentAnnals Of Oncology, 2010
- Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialThe Lancet Oncology, 2010
- Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomyBreast Cancer Research and Treatment, 2010
- The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerBritish Journal of Cancer, 2010
- Prospective Comparison of Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast CancerClinical Cancer Research, 2010
- Familial Breast CancerAmerican Journal of Clinical Oncology, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor CharacteristicsJNCI Journal of the National Cancer Institute, 2008
- Impact of Preoperative Versus Postoperative Chemotherapy on the Extent and Number of Surgical Procedures in Patients Treated in Randomized Clinical Trials for Breast CancerAnnals of Surgery, 2006